The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Australian stem-cell and regenerative medicine company, Cynata Therapeutics, to continue its Phase I clinical trial of CYP-001 to treat steroid-resistant graft-versus-host disease (GvHD).

Cynata’s CYP-001 has been derived from allogeneic induced pluripotent stem cells (iPSCs), which are the man-made versions of embryonic stem cells.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

They have the ability to reproduce themselves indefinitely, as well as differentiate into any other type of cell in the body. It can be expanded without limits and stored for a longer duration.

"The trial will involve approximately 16 subjects who underwent bone marrow transplant or similar procedure, and who were also diagnosed with steroid-resistant Grade II-IV acute GvHD."

The Phase I trial has been titled as 'An Open-Label Phase I Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease'.

The trial will involve approximately 16 subjects who underwent bone marrow transplant or similar procedure, and who were also diagnosed with steroid-resistant Grade II-IV acute GvHD.

See Also:

Cynata product development vice-president Dr Kilian Kelly said: "We are delighted that the MHRA has approved our clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Not only does this enable us to start providing our highly promising therapy to patients with a particularly devastating disease, it also provides clear validation of our manufacturing process and preclinical development programme from one of the most highly regarded regulatory authorities worldwide."